David R. Doherty
Papers
1
Total Citations
33
H-Index
1
About
David R. Doherty is a distinguished researcher whose work bridges clinical pharmacology and biomarker development, with a primary focus on bone metabolism and therapeutic interventions. His key research areas include the validation and application of biomarkers in drug development, particularly in osteoporosis and metabolic bone diseases. Doherty’s major contribution lies in advancing the use of C-terminal telopeptides of type 1 collagen (CTX-1) as a fit-for-purpose biomarker, as demonstrated in his highly cited 2009 study on denosumab clinical trials—a pivotal work that has garnered 33 citations. This research established rigorous methodological validation standards, enabling more accurate monitoring of bone resorption in patients receiving denosumab, a groundbreaking monoclonal antibody therapy. By integrating biomarker science with clinical endpoints, Doherty has helped streamline drug efficacy assessments and reduce reliance on traditional imaging outcomes. His work exemplifies the translational power of biomarkers in personalized medicine, offering researchers and clinicians a robust framework for evaluating therapeutic responses. Doherty’s achievements underscore his role in shaping evidence-based approaches to bone health, making his contributions essential reading for students and professionals in pharmacology, rheumatology, and clinical trial design.
Research Focus
Key Achievements
Top Papers
- 1